Final Di-Gesic hearing Feb
November 13, 2012
ASPEN Australia has confirmed
that doctors can continue to
prescribe Doloxene and Di-Gesic,
with a final Administrativer Appeals
Tribunal (AAT) hearing over the
cancellation now set down for 27-
28 February 2013.
Aspen is appealing against the
deregistration of painkillers
containing dextropropoxyphene
(DPP), and a stay has been granted
by the AAT while the appeal
continues (PD 13 Sep).
The company’s md, Greg Lan, said
that Aspen understands that like
many other prescription and OTC
drugs, DPP has the potential to
cause harm if it is not used
appropriately.
“However we support DPP being
available to patients who need it,
and who will be left without
satisfactory pain relief if DPP is
removed from the market”.
He said Aspen has received
feedback from many doctors,
pharmacists and patients “who
support the steps the company has
taken to ensure DPP remains
available, and who recognise the
Final Di-Gesic hearing Feb
difficulty that some patients will
suffer if it is no longer available”.
The company said doctors who
continue to subscribe DPPcontaining
painkillers should
carefully consider the indications,
warnings and contraindications in
the Product Information and
Consumer Medicines Information.
The above article was sent to subscribers in Pharmacy Daily's issue from 13 Nov 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Nov 12
